New York is currently home to 4503 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis
Recruiting
The purpose of the study is to identify the recommended Part 2 dose (R2PD) of imetelstat sodium in combination with ruxolitinib in participants with myelofibrosis (MF) in Part 1, and to evaluate the safety and clinical activity of the R2PD of imetelstat sodium in combination with ruxolitinib or other Janus Kinase (JAK) inhibitors in participants with MF in Part 2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Myelofibrosis
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
Recruiting
This study will look at whether monitoring HPV ctDNA levels is an effective way to detect cancer relapse risk in people with HPV-OPC. All participants will have recently had surgery to treat their disease, or they will be scheduled to have this surgery. In Arm A the researchers will see whether monitoring participants' HPV ctDNA levels can safely identify patients who do not need radiation therapy (RT) after surgery and whose RT can be delayed until their HPV ctDNA levels become detectable. In... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities), Commack, New York
Conditions: HPV, Oropharynx Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Achieving Meaningful Clinical Benchmarks With Ekso Gait Training During Acute Stroke Inpatient Rehabilitation.
Recruiting
The Ekso (Ekso Bionics) is a wearable exoskeleton that provides robotic support and walking assistance for patients with lower extremity paralysis. Research suggests that exoskeleton-assisted gait training is as effective as conventional gait training at improving walking outcomes and balance during both the chronic and subacute period following stroke (Goffredo et al., 2019; Molteni et al., 2017; Molteni et al., 2021; Nam et al., 2019; Rojek, 2019). Exoskeleton-assisted gait training during ac... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Sunnyview, Schenectady, New York
Conditions: Stroke, Stroke, Acute, Cerebrovascular Accident, Cerebrovascular Accident, Acute
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
Recruiting
The purpose of this study is to see if the combination of 177Lu-girentuximab and nivolumab is a safe and effective treatment for advanced clear cell renal cell carcinoma/ccRCC that has the CAIX protein.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities), Commack, New York
Conditions: Clear Cell Renal Cell Carcinoma, Kidney Cancer, Advanced Renal Cell Carcinoma
Clinical Trial of Approaches to Prostate Cancer Surgery
Recruiting
This is a prospective, randomized controlled trial to compare cancer control and health-related quality of life following pelvic fascia-sparing radical prostatectomy versus standard radical prostatectomy. The investigators hypothesize that pelvic fascia-sparing radical prostatectomy will have similar cancer control (primary outcome) and sexual function outcomes; and significantly better urinary function, penile shortening/deformity and inguinal hernia risks as compared to radical prostatectomy.
Gender:
MALE
Ages:
Between 40 years and 80 years
Trial Updated:
05/14/2025
Locations: NewYork-Presbyterian Queens, Flushing, New York
Conditions: Prostate Cancer
Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery
Recruiting
The purpose of the study is to explore adding the study drug certolizumab to standard chemotherapy as it may reduce the inflammation caused by the cancer and make the chemotherapy more effective in shrinking the cancer. This study will examine whether adding certolizumab to the usual treatment approach is better than, the same as, or worse than the usual approach alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activity), Commack, New York
Conditions: Lung Cancer, Lung Cancer Stage II, Lung Cancer Stage III
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
Recruiting
The purpose of this study is to translate and tailor for Latinx participants a program called Communicating with Oncology Nurses about Values from the Outset (CONVO). In CONVO, routine cancer care for each participant includes a discussion between the nurse and participant about the participant's health-related values.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
05/14/2025
Locations: SBH Health System, Bronx, New York
Conditions: Solid Tumor, Solid Tumor, Adult, Solid Tumor, Unspecified, Adult
A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma
Recruiting
The purpose of this study is to find out whether IMPRINT in combination with pembrolizumab is a safe treatment for people with malignant pleural mesothelioma (MPM).The highest dose of IMPRINT that causes few or mild side effects when given in combination with pembrolizumab will be found. Once the highest safe dose of IMPRINT is found, it will be tested in combination with pembrolizumab in future participants to see whether the combination may be an effective treatment for MPM.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities), Commack, New York
Conditions: Malignant Pleural Mesothelioma
A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)
Recruiting
A Global Phase III multicenter, randomized, assessor-blinded, active-controlled designed to evaluate safety and efficacy of study drug for the treatment of the MPS II.
Gender:
ALL
Ages:
All
Trial Updated:
05/14/2025
Locations: Columbia University, New York City, New York
Conditions: Mucopolysaccharidosis II
Selective Laryngeal Reinnervation for Bilateral Vocal Fold Paralysis
Recruiting
This is a prospective observational study examining the treatment outcomes of selective laryngeal reinnervation procedures for patients with bilateral vocal fold paralysis.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/14/2025
Locations: Sean Parker Institute for the Voice, New York, New York
Conditions: Bilateral Vocal Cord Paralysis
RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy
Recruiting
Chemotherapy-induced nausea and vomiting (CINV) are among the most bothersome symptoms during cancer treatment according to children and their parents. Most children receiving highly emetogenic chemotherapy (HEC), including those receiving hematopoietic stem cell transplant (HSCT) conditioning, experience CIV despite receiving antiemetic prophylaxis. Olanzapine improves CINV control in adult cancer patients, has a track record of safe use in children with psychiatric illness, does not interact w... Read More
Gender:
ALL
Ages:
Between 30 months and 18 years
Trial Updated:
05/14/2025
Locations: Columbia University/Morgan Stanley Children's Hospital, New York, New York
Conditions: Vomiting in Infants and/or Children, Nausea, Hematopoietic System--Cancer, Oncology
A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM
Recruiting
An observational study to assess real-world patient characteristics and clinical course of disease in participants with PKP2-ACM.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/13/2025
Locations: University of Rochester, Rochester, New York
Conditions: Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC